• AeroVironment, Inc. has in recent weeks faced a wave of securities class action lawsuits tied to the terminated SCAR program and a large goodwill impairment in its space division, even as it secured new Air Force Research Laboratory contracts and announced multi-million-dollar manufacturing expansions in Ohio, Alabama, and New Mexico.
• The contrast between legal challenges around past SCAR-related disclosures and active investment in advanced biomanufacturing, ceramics, and counter‑UAS production highlights how AeroVironment’s risk profile now sits alongside a growing footprint in high-priority defense technologies and domestic manufacturing.
• We’ll now examine how these SCAR-related lawsuits and the shift in U.S. Space Force procurement could reshape AeroVironment’s investment narrative and risk balance.

Find 47 companies with promising cash flow potential yet trading below their fair value.

AeroVironment Investment Narrative Recap

To own AeroVironment today, you have to believe its growing role in high‑priority defense tech and domestic manufacturing can outweigh execution and contract‑concentration risks. In the near term, the key catalyst is converting its record backlog and new programs into profitable growth, while the biggest risk is the cluster of SCAR‑related lawsuits and the U.S. Space Force’s shift to multi‑vendor, lower cost solutions. The recent legal filings appear material to that risk balance, not the core growth thesis.

Among the latest announcements, the US$15 million expansion in Greene County, Ohio is especially relevant. It reinforces AeroVironment’s bet on advanced biotechnology and materials manufacturing tied to Air Force Research Laboratory contracts, which sits in sharp contrast to the SCAR program turmoil. For investors focused on catalysts, it underscores how AeroVironment is leaning into areas like biomanufacturing and advanced ceramics that align directly with current defense technology priorities.

Yet despite these expansion plans, investors should also be aware that the SCAR contract termination and related securities lawsuits could still materially affect...

AeroVironment's narrative projects $2.8 billion revenue and $205.9 million earnings by 2029.

Uncover how AeroVironment's forecasts yield a $311.47 fair value, a 69% upside to its current price.

Exploring Other Perspectives

While consensus focuses on contract risk and manufacturing buildout, the most optimistic analysts were assuming revenue could reach about US$2.9 billion with earnings near US$380 million, so this SCAR shock and legal overhang may push you to reconsider whether that kind of upside or a more cautious path feels closer to your own view.

Explore 15 other fair value estimates on AeroVironment - why the stock might be worth 23% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AeroVironment research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free AeroVironment research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AeroVironment's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.